An insilco approach to venous thromboembolism (VTE) using network based medicine with direct oral anticoagulants (DOACS)

ABSTRACT

Background: Thromboembolism is characterized by aberrant activation of coagulation pathways often results in thrombus or clot formation in the large blood vessels followed by dislodgement from the primary site of formation into the distal site. Thromboembolism is of two types;1. arterial thromboembolism (ATE) and 2. venous thromboembolism (VTE). Direct oral anticoagulants (DOACs) are the greatest innovation in the field of anticoagulation therapy. It has several advantages when compared to traditional vitamin antagonists (VKA). COVID Patients are at greater risk of thromboembolic complications. So, Direct oral anticoagulants such as Rivaroxaban and Apixaban are the two choices for clinicians firstly because it has greater advantages over Vitamin K antagonists (VKA) as they have broader therapeutic window and secondly because they don ' t require monitoring hence there is less patients visits for blood sample withdrawal thus minimizing the spread of infection. Aims: The aim of our study was to decipher the underlying molecular mechanisms in venous thromboembolism (VTE) and establishing the connection of certain miRNAs and treatment with DOACs. To overcome the potential bleeding episodes in patients who are prone to bleeding epistaxis and intracranial hemorrhages (ICH). Methods: We obtained a raw datasets of Differentially expressed genes (DEG 's) from NCBI in patients with who are diagnosed with Venous Thromboembolisms (VTE) which were then further subjected to statistical analysis based on p-value and Log fold changes. Results: The table 1 shows the molecular docking results of pglycoprotein and the anticoagulant Rivaroxaban(Anti-Xa). Conclusions: Metabolism of the dug in the human body is a complex mechanism that are govern by several mechanisms including dietary intake & concomitant administration of drugs. There are number of enzymes involved in the biotransformation of a drug into active compounds capable of exerting therapeutic responses.